ストックスクリーナーアプリを入手
236.28
2.98%
6.83
プレマーケット:
236.41
0.13
+0.06%
前日終値:
$229.45
開ける：
$230.545
24時間の取引高:
7.98M
Relative Volume:
1.41
時価総額：
$417.60B
収益：
$59.64B
当期純損益:
$2.36B
株価収益率:
178.28
EPS:
1.3253
ネットキャッシュフロー:
$19.68B
1週間 パフォーマンス:
+1.69%
1か月 パフォーマンス:
+2.11%
6か月 パフォーマンス:
+29.97%
1年 パフォーマンス:
+37.59%
1日の値動き範囲:
$230.14
$238.01
1週間の範囲:
$228.00
$238.15
52週間の値動き範囲:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
ABBV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
236.28 | 405.53B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,059.70 | 933.76B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
203.90 | 489.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
127.31 | 238.62B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
97.76 | 235.72B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-04 | ダウングレード | DZ Bank | Buy → Hold |
| 2025-10-14 | ダウングレード | Erste Group | Buy → Hold |
| 2025-10-01 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-08-12 | 再開されました | Piper Sandler | Overweight |
| 2025-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - The Globe and Mail
Top Research Reports for JPMorgan Chase, Netflix & AbbVie - Yahoo Finance
ABBV latest news: price expected to consolidate near highs — upside breakout may target $240 - Traders Union
How AbbVie Inc. stock performs in easing cycles2025 EndofYear Setup & Daily Growth Stock Investment Tips - newser.com
Lip Augmentation Market to Witness Massive Growth by 2032 | - openPR.com
How AbbVie Inc. stock compares with tech leadersJuly 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
AbbVie Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Unpacking the Latest Options Trading Trends in AbbVieAbbVie (NYSE:ABBV) - Benzinga
How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressure - newser.com
The Escalator: AbbVie, Sonoma Biotherapeutics, Way Better Partners and more - Medical Marketing and Media
Is AbbVie Inc. (4AB) stock a buy before earnings resultsWeekly Stock Recap & Weekly Return Optimization Alerts - newser.com
How supply chain issues affect AbbVie Inc. stockPortfolio Update Summary & Safe Capital Investment Plans - newser.com
Will AbbVie Inc. (4AB) stock profit from AI boomChart Signals & Reliable Price Action Trade Plans - newser.com
Why AbbVie Inc. stock appears on watchlistsMarket Performance Summary & Fast Moving Stock Watchlists - newser.com
Why millennials buy AbbVie Inc. (Common Stock) (4AB0) stockPortfolio Performance Summary & Short-Term High Return Ideas - newser.com
How geopolitical risks impact AbbVie Inc. (Common Stock) (4AB0) stock2025 Volume Leaders & Technical Confirmation Trade Alerts - newser.com
Can AbbVie Inc. stock weather global recession2025 Price Momentum & Smart Money Movement Tracker - newser.com
Why AbbVie Inc. (4AB) stock stays resilientShare Buyback & Verified Entry Point Detection - newser.com
How higher bond yields impact AbbVie Inc. stockEarnings Risk Report & AI Driven Stock Reports - newser.com
Is AbbVie Inc. stock undervalued at current priceJuly 2025 Patterns & Free Fast Entry Momentum Trade Alerts - newser.com
Is AbbVie Inc. stock undervalued vs historical averagesTrade Ideas & Real-Time Chart Breakout Alerts - newser.com
Is AbbVie Inc. (4AB) stock undervalued after correctionInflation Watch & Daily Oversold Bounce Ideas - newser.com
Can AbbVie Inc. stock sustain revenue growthDay Trade & Smart Allocation Stock Tips - newser.com
How reliable is AbbVie Inc. (4AB) stock dividend growthIPO Watch & Stepwise Entry and Exit Trade Signals - newser.com
Will AbbVie Inc. stock announce special dividendPortfolio Growth Summary & Weekly Top Gainers Trade List - newser.com
How AbbVie Inc. (Common Stock) (4AB0) stock performs during market turbulencePortfolio Update Report & High Yield Stock Recommendations - newser.com
AbbVie, Genmab's Epkinly gets FDA nod for pivotal lymphoma treatment - Crain's Chicago Business
Why Johnson & Johnson's Share Price Is Popping This Month - The Motley Fool
Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis BiotherapeuticsResearchAndMarkets.com - The AI Journal
How AbbVie Inc. (4AB) stock benefits from digital adoptionQuarterly Profit Review & Free Expert Approved Momentum Trade Ideas - newser.com
Can AbbVie Inc. (Common Stock) (4AB0) stock retain market dominanceInflation Watch & Safe Entry Point Identification - newser.com
AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell? - Yahoo Finance
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Healthcare Rotation Underway: 3 Stocks Leading the Charge - MarketBeat
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3 - sharewise.com
Approvals extend use of Roche, AbbVie drugs in lymphoma - pharmaphorum
Will AbbVie Inc. stock outperform Dow Jones2025 Earnings Surprises & Fast Momentum Entry Tips - newser.com
Will AbbVie Inc. stock maintain strong growthJuly 2025 Opening Moves & Short-Term High Return Ideas - newser.com
Glenmark 3.0 In The Making, Invigorated By IGI-AbbVie Deal - Citeline News & Insights
Is AbbVie Inc. reversing from oversold territoryQuarterly Trade Summary & Weekly Top Gainers Trade List - newser.com
How AbbVie Inc. stock trades before earningsJuly 2025 Earnings & Daily Risk Controlled Trade Plans - newser.com
Is AbbVie’s 30% 2025 Surge Justified by Its Latest Drug Pipeline Wins? - Yahoo Finance
AbbVie Gets FDA Approval for Epkinly Combo for Relapsed Follicular Lymphoma - MarketScreener
AbbVie Announces U.S. FDA Approval of EPKINLY® in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma - Investing News Network
FDA approves AbbVie’s EPKINLY combination therapy for lymphoma By Investing.com - Investing.com Canada
FDA Approves AbbVie's EPKINLY for Follicular Lymphoma Treatment - GuruFocus
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma - WV News
FDA Expands Approval for AbbVie's (ABBV) Epkinly in Lymphoma Tre - GuruFocus
AbbVie, Genmab win FDA label expansion for Epkinly in follicular lymphoma - Seeking Alpha
Global drugmakers rush to boost US presence as tariff threat looms - Reuters
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73 - simplywall.st
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
大文字化:
|
ボリューム (24 時間):